Assignee
GLYCOTOPE GMBH
DE·8 granted patents·17 pending applications·52 citations·filing 2003–2025
Top patents by PatentIndex Score
25 records- 0189US9845361B2Recognition molecules for the treatment and detection of tumorsGLYCOTOPE GMBH·Filed 2014·Granted Dec 19, 2017·8 cites·7 claims
- 0287US10280230B2Use of human cells of myeloid leukemia origin for expression of antibodiesGLYCOTOPE GMBH·Filed 2015·Granted May 7, 2019·5 cites·37 claims
- 0385US9345794B2Tumor-specific recognition moleculesGLYCOTOPE GMBH·Filed 2013·Granted May 24, 2016·5 cites·22 claims
- 0482US7595192B2Process for the production of temperature-induced tumor cell lysates for use as immunogenic compoundsGLYCOTOPE GMBH·Filed 2003·Granted Sep 29, 2009·21 cites·39 claims
- 0578US8017388B2Tumour cell lines and uses thereofGLYCOTOPE GMBH·Filed 2004·Granted Sep 13, 2011·13 cites·13 claims
- 0674US2025257149A1Anti-muc1 antibodyGLYCOTOPE GMBH·Filed 2025·Application pending·0 cites
- 0769US9487567B2Method for the production of an immunostimulating mucin (MUC1)GLYCOTOPE GMBH·Filed 2014·Granted Nov 8, 2016·0 cites·7 claims
- 0867US12297289B2Anti-MUC1 antibodyGLYCOTOPE GMBH·Filed 2019·Granted May 13, 2025·0 cites·37 claims
- 0960US2019359731A1Use of human cells of myeloid leukaemia origin for expression of antibodiesGLYCOTOPE GMBH·Filed 2019·Application pending·0 cites
- 1053US2016068609A1Anti-cancer treatments with anti-egfr antibodies having a low fucosylationGLYCOTOPE GMBH·Filed 2014·Application pending·0 cites
- 1150US2016304577A1Glycosylated glycophorin peptidesGLYCOTOPE GMBH·Filed 2014·Application pending·0 cites
- 1243US2015166664A1Novel therapeutic treatments with anti-her2 antibodies having a low fucosylationGLYCOTOPE GMBH·Filed 2013·Application pending·0 cites
- 1342US2020087410A1Humanized anti-cd40 antibodiesGLYCOTOPE GMBH·Filed 2018·Application pending·0 cites
- 1441US2021107961A1Fusion Protein Constructs Comprising an Anti-MUC1 Antibody and IL-15GLYCOTOPE GMBH·Filed 2019·Application pending·0 cites
- 1540US2018264086A1Mammalian follicle-stimulating hormone composition with increased stabilityGLYCOTOPE GMBH·Filed 2016·Application pending·0 cites
- 1640US2015353959A1Peptides for enhancing protein expressionGLYCOTOPE GMBH·Filed 2014·Application pending·0 cites
- 1738US2019343953A1Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitorGLYCOTOPE GMBH·Filed 2018·Application pending·0 cites
- 1838US2017035854A1Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormoneGLYCOTOPE GMBH·Filed 2015·Application pending·0 cites
- 1937US2018230552A1Method for Detecting Nucleic Acids in Samples Containing Biological MaterialGLYCOTOPE GMBH·Filed 2015·Application pending·0 cites
- 2037US2020148785A1Pd-l1 and ta-muc1 antibodiesGLYCOTOPE GMBH·Filed 2018·Application pending·0 cites
- 2137US2020131275A1Multispecific antibody constructs binding to muc1 and cd3GLYCOTOPE GMBH·Filed 2018·Application pending·0 cites
- 2235US10184135B2Eukaryotic expression vectors comprising regulatory elements of the globin gene clustersGLYCOTOPE GMBH·Filed 2016·Granted Jan 22, 2019·0 cites·23 claims
- 2335US2018028680A1Glycooptimized antibody drug conjugatesGLYCOTOPE GMBH·Filed 2016·Application pending·0 cites
- 2433US2018135091A1Small scale cultivation method for suspension cellsGLYCOTOPE GMBH·Filed 2016·Application pending·0 cites
- 2528US2018216093A1Heteromers comprising antibody domain fusion proteinsGLYCOTOPE GMBH·Filed 2016·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →